{"filing":{"accession_number":"0001193125-26-303190","cik":"0001585608","ticker":"JAGX","company_name":"Jaguar Health, Inc.","form":"8-K","filing_date":"2026-07-14","report_date":null,"primary_document":"d144017d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526303190/d144017d8k.htm"},"events":[{"id":17861,"run_id":16022,"accession_number":"0001193125-26-303190","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Jaguar Health's subsidiary Napo entered into a new three-year manufacturing and supply agreement with Alivus on July 9, 2026, to continue supplying crofelemer for Mytesi®, the company's FDA-approved prescription drug product. This is a material definitive agreement that secures the supply chain for the company's primary commercial product and includes minimum purchase commitments with potential financial obligations. While this is a renewal rather than a new relationship, the binding three-year commitment with specified minimum quantities and financial penalties for shortfalls constitutes a material agreement affecting the company's operational and financial obligations.","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-07-14","form":"8-K","submitted_at":null,"items":[{"id":16487,"accession_number":"0001193125-26-303190","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Jaguar Health's subsidiary Napo entered into a new three-year manufacturing and supply agreement with Alivus on July 9, 2026, to continue supplying crofelemer for Mytesi®, the company's FDA-approved prescription drug product. This is a material definitive agreement that secures the supply chain for the company's primary commercial product and includes minimum purchase commitments with potential financial obligations. While this is a renewal rather than a new relationship, the binding three-year commitment with specified minimum quantities and financial penalties for shortfalls constitutes a material agreement affecting the company's operational and financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T20:16:37.339990+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16487,"accession_number":"0001193125-26-303190","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Jaguar Health's subsidiary Napo entered into a new three-year manufacturing and supply agreement with Alivus on July 9, 2026, to continue supplying crofelemer for Mytesi®, the company's FDA-approved prescription drug product. This is a material definitive agreement that secures the supply chain for the company's primary commercial product and includes minimum purchase commitments with potential financial obligations. While this is a renewal rather than a new relationship, the binding three-year commitment with specified minimum quantities and financial penalties for shortfalls constitutes a material agreement affecting the company's operational and financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T20:16:37.339990+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-07-14"}]}